Author:
Coriat Romain,Mir Olivier,Camps Sandra,Ropert Stanislas,Billemont Bertrand,Leconte Mahaut,Larousserie Frédérique,Anract Philippe,Alexandre Jérôme,Goldwasser François
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference27 articles.
1. Furlanut M, Franceschi L (2003) Pharmacology of ifosfamide. Oncology 65(Suppl 2):2–6
2. Cohen MH, Creaven PJ, Tejada F, Hansen HH, Muggia F, Mittelman A et al (1975) Phase I clinical trial of isophosphamide (NSC-109724). Cancer Chemother Rep 59(4):751–755
3. Lind MJ, Roberts HL, Thatcher N, Idle JR (1990) The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother Pharmacol 26(2):105–111
4. Cerny T, Castiglione M, Brunner K, Kupfer A, Martinelli G, Lind M (1990) Ifosfamide by continuous infusion to prevent encephalopathy. Lancet 335(8682):175
5. Wagner T, Zink M, Schwieder G (1987) Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide. J Cancer Res Clin Oncol 113(2):160–165
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献